CCIA
ACRS icon

Cherry Creek Investment Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Cherry Creek Investment Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,440
Closed -$166K – 102
2021
Q4 		$166K Sell
11,440
-1,075
-9% -$16.3K 0.1% 107
2021
Q3 		$225K Buy
+12,515
New +$201K 0.15% 97

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Cherry Creek Investment Advisors's ACRS Position: Q1 2022 in Review

Cherry Creek Investment Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 11,440 shares — an estimated $166K sold.

Cherry Creek Investment Advisors first reported a position in ACRS in Q3 2021 and held it in 2 quarters. The position peaked at $225K in Q3 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Cherry Creek Investment Advisors reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cherry Creek Investment Advisors sold 11,440 Aclaris Therapeutics shares in Q1 2022, an estimated $166K.
  • Cherry Creek Investment Advisors first reported a position in Aclaris Therapeutics in Q3 2021 and held it in 2 quarters.
  • Cherry Creek Investment Advisors's Aclaris Therapeutics position peaked at $225K in Q3 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Cherry Creek Investment Advisors's 13F filing for Q1 2022, filed 22 Apr 2022.